Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Published

To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
Experimental and clinical psychopharmacology
Date
2023-04-01
Source
PubMed
DOI
10.1037/pha0000597
PubMed
36048112

Authors

Christensen JAFipps DCBostwick JM
Watch author

Derived topics and classifications

psilocybin AddictionBrain ImagingReview ArticleSafety Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.2023-04-01

Related papers

Exposure to Potent Hallucinogens in an AdolescentThe Primary Care Companion For CNS Disorders · 2013-10-23Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.The primary care companion for CNS disorders · 2024-01-16Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa.Journal of eating disorders · 2025-05-26Psychedelics in the treatment of unipolar and bipolar depression.International journal of bipolar disorders · 2022-07-05Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleClinicalTrials.gov · 2026-05-12Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms.Journal of affective disorders · 2026-05-01Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use DisorderClinicalTrials.gov · 2026-03-30Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.CNS & neurological disorders drug targets · 2026-03-11